Disc Medicine Stock (IRON) Soars Over 28% on a Phase 3 Trial Win
Disc Medicine stock gained on Monday following new clinical trial results that met primary and secondary endpoints.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 2,450,221 | $160,391,467 | 1.61% | |
| 2. | Vestal Point Capital Ryan Wilder | 1,635,000 | $107,027,100 | +6% | 2.77% |
| 3. | Opaleye Management James A. Silverman | 1,095,000 | $71,678,700 | +29% | 8.07% |
| 4. | Logos Capital Arsani William | 1,015,000 | $66,441,900 | +16% | 3.46% |
| 5. | Woodline Partners Michael Rockefeller And Karl Kroeker | 958,281 | $62,729,074 | 0.19% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $36.00 | 222,223 | $8,000,028.00 | 420,549 | 2024-06-17 | Filing | |
| $36.00 | 10,986 | $395,496.00 | 235,391 | 2024-06-17 | Filing | |
| $36.00 | 43,944 | $1,581,984.00 | 941,569 | 2024-06-17 | Filing | |
| $36.00 | 28,404 | $1,022,544.00 | 608,611 | 2024-06-17 | Filing | |
| $36.00 | 10,986 | $395,496.00 | 235,391 | 2024-06-17 | Filing |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $85.09 | 16,035 | $1,364,437.39 | 63,445 | 2026-11-10 | Filing | |
| $80.23 | 266 | $21,341.18 | 12,991 | 2026-10-21 | Filing | |
| $80.23 | 11,470 | $920,238.10 | 293,430 | 2026-10-21 | Filing | |
| $80.23 | 13,783 | $1,105,810.09 | 296,277 | 2026-10-21 | Filing | |
| $79.95 | 55 | $4,397.25 | 13,257 | 2026-10-20 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,803,145 | $314,413,870 | 0.01% | |
| 2. | 2,532,863 | $165,801,211 | 0% | |
| 3. | 1,812,170 | $119,497,054 | 0.01% | |
| 4. | 1,756,490 | $114,979,835 | 0.02% | |
| 5. | 1,405,446 | $92,000,495 | 0% |